Ref (type)	Population	Outcome, Interventions	Results and statistical analysis	Effect size	Favours
Symptom severity
Systematic review	266 people 3 RCTs in this analysis	Weighted mean difference in Positive and Negative Syndrome Scale (PANSS) positive endpoint score with risperidone (dose range 2–16 mg/day) with placebo Absolute results not reported	Mean difference +1.67 95% CI –2.93 to +6.28		Not significant
Systematic review	266 people 3 RCTs in this analysis	Weighted mean difference in PANSS negative endpoint score with risperidone (dose range 2–16 mg/day) with placebo Absolute results not reported	Mean difference –0.90 95% CI –3.06 to +1.27		Not significant
Systematic review	233 people Data from 1 RCT	Weighted mean change from baseline in PANSS positive score with risperidone (mean dose 4.7 mg/day [SD 0.9 mg/day]) with placebo Absolute results not reported	Mean difference 2.8 95% CI 2.62 to 2.98	Effect size not calculated	risperidone
Systematic review	233 people Data from 1 RCT	Weighted mean change from baseline in PANSS negative score with risperidone (mean dose 4.7 mg/day [SD 0.9 mg/day]) with placebo Absolute results not reported	Mean difference 0.5 95% CI 0.35 to 0.65	Effect size not calculated	risperidone
Systematic review	160 adolescents Data from 1 RCT	Mean change from baseline in PANSS positive symptom score 6 weeks with risperidone (1–3 mg/day) with placebo Absolute results not reported	Mean difference –3.6 95% CI –5.6 to –1.5	Effect size not calculated	risperidone
Systematic review	160 adolescents Data from 1 RCT	Mean change from baseline in PANSS positive symptom score 6 weeks with risperidone (4–6 mg/day) with placebo Absolute results not reported	Mean difference –4.1 95% CI –6.2 to –2.0	Effect size not calculated	risperidone
Systematic review	160 adolescents Data from 1 RCT	Mean change from baseline in PANSS negative symptom score 6 weeks with risperidone (1–3 mg/day) with placebo Absolute results not reported	Mean difference –3.2 95% CI –4.8 to –1.5	Effect size not calculated	risperidone
Systematic review	160 adolescents Data from 1 RCT	Mean change from baseline in PANSS negative symptom score 6 weeks with risperidone (4–6 mg/day) with placebo Absolute results not reported	Mean difference –2.8 95% CI –4.5 to –1.1	Effect size not calculated	risperidone